COVID-19 Vaccine Efficacy Over Time: Severe Disease in Hospitalized Patients
Radiology,
Год журнала:
2024,
Номер
310(1)
Опубликована: Янв. 1, 2024
Язык: Английский
Secondary Infections in Patients with COVID-19 Pneumonia Treated with Tocilizumab Compared to Those Not Treated with Tocilizumab: A Retrospective Study at a Tertiary Hospital in Kenya
International Journal of General Medicine,
Год журнала:
2022,
Номер
Volume 15, С. 2415 - 2425
Опубликована: Март 1, 2022
From
the
first
case
of
SARS-Co-2
in
Wuhan,
China,
to
virus
being
declared
as
a
pandemic
March
2020,
world
has
witnessed
morbidity
and
mortality
on
global
scale.
Scientists
have
worked
at
record
pace
deliver
vaccine
for
prevention
this
deadly
disease.
Tocilizumab,
an
interleukin-6
(IL-6)
blocker,
received
emergency
use
authorization
(EUA)
by
Federal
Drug
Agency
(FDA)
June
2021.This
retrospective
observational
cohort
study
was
conducted
Aga
Khan
University
Hospital,
Nairobi,
from
8,
December
31,
2020.
All
patients
with
PCR
confirmed
COVID-19
pneumonia
were
included.
Data
obtained
medical
records,
admission
registry
used
identify
patients,
both
their
electronic
paper-based
files
retrieved
records.
Patient
demographic
data,
history,
baseline
comorbidities,
clinical
characteristics,
outcome
data
collected
infectious
complications
Tocilizumab
affected
pneumonia.A
total
913
who
diagnosed
The
overall
superinfection
infection
rate
among
6%.
Superinfection
17.2%
non-Tocilizumab
group
4.8%.
severe
critically
ill
even
higher
41.8%
69.9%
(Tocilizumab
group)
2.1%
11.8%
(non-Tocilizumab
group),
respectively
(p
<
0.001).
There
no
difference
observed
between
groups
=
0.846).
Infection
HIV
co-infection
very
low
2.3%.Contrary
some
studies,
group,
group.
remains
susceptible
population.
Язык: Английский
Inflammation in COVID-19: A Risk for Superinfections
COVID,
Год журнала:
2022,
Номер
2(11), С. 1609 - 1624
Опубликована: Ноя. 18, 2022
The
worldwide
coronavirus
pandemic
has
been
one
of
the
most
significant
health
crisis
threats
in
recent
years.
COVID-19
not
only
cause
mortality
this
pandemic.
A
dangerous
but
frequent
complication
viral
infections
is
secondary
superinfection
or
superimposed
bacterial
infection.
Despite
lacking
data
on
prevalence,
microbiology,
and
outcomes
co-infection
superinfection,
limited
publications
have
reported
high
incidence
severe
infection
patients
its
effect
mortality.
Those
who
clinical
symptoms
disease,
others
requiring
prolonged
stay
intensive
care
units
(ICU),
are
more
susceptible
to
developing
superinfections
by
nosocomial
pathogens.
Ventilator-acquired
pneumonia
(VAP)
common
type
observed
among
patients,
followed
bacteraemia
with
sepsis,
urinary
tract
(UTI).
There
an
urgent
need
for
prospective
studies
provide
epidemiological,
clinical,
microbiological
superinfections,
which
can
be
used
form
effective
antimicrobial
guidelines
that
could
important
role
disease
outcomes.
Язык: Английский